Premium
Prostate cancer metabolite quantification relative to water in 1 H‐MRSI in vivo at 3 Tesla
Author(s) -
McLean Mary A.,
Barrett Tristan,
Gnanapragasam Vincent J.,
Priest Andrew N.,
Joubert Ilse,
Lomas David J.,
Neal David E.,
Griffiths John R.,
Sala Evis
Publication year - 2011
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.22703
Subject(s) - choline , in vivo , metabolite , creatine , nuclear magnetic resonance , magnetic resonance imaging , prostate cancer , magnetic resonance spectroscopic imaging , prostate , chemistry , nuclear medicine , medicine , cancer , radiology , physics , biology , biochemistry , microbiology and biotechnology
1 H magnetic resonance spectroscopic imaging was performed on 16 men with suspected prostate cancer using an 8‐channel external receive coil at 3 T. Choline and citrate (Cit) signals were measured in prostate lesions and normal‐appearing peripheral zone as identified on T 2 ‐weighted images. Metabolites were quantified relative to unsuppressed water from a separately acquired magnetic resonance spectroscopic imaging dataset using LCModel. Validation experiments were also performed in a phantom containing physiological concentrations of choline, Cit, and creatine. In vitro, fair agreement between measured and true concentrations was observed, with the greatest discrepancy being a 35% underestimation of Cit. In vivo, one dataset was rejected for failure to meet the quality criterion of linewidth <15 Hz, and in 6 of 15 subjects, insufficient normal‐appearing peripheral zone tissue was identified for study. Lesions were found to have higher choline and choline/Cit, and lower Cit, than normal‐appearing peripheral zone. The smaller skew of data obtained using water normalization in comparison with metabolite ratios suggests potential usefulness in longitudinal tumor monitoring and in studies of treatment effects. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.